The East Bay Innovation Award is sponsored jointly by The East Bay Economic Development Alliance and the San Francisco Business Times, and celebrates the cutting-edge businesses that make the East Bay one of the preeminent regions of innovation in the U.S.
"We are very pleased to receive this award that recognizes our achievements in innovation and our contribution to the Bay Area. Our company vision is Value through Innovation and this award is an example of how we provide value, not only to our patients, but also to the East Bay," said Michael Howaldt, Vice President, Biopharmaceuticals Operations USA and Fremont Site Head.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies with net sales of about 14.7 billion Euros in 2012. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
All activities of the biopharmaceutical contract manufacturing are performed within the Boehringer Ingelheim Biopharmaceuticals GmbH, headquartered in Ingelheim, Germany and are represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience - the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China).
Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle-transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.